EGFR and non-small cell lung carcinoma: However, patients with advanced NSCLC treated with first- and second-generation EGFR TKIs inevitably develop acquired resistance, with the most common mechanism being a threonine-to-methionine substitution (T790M) secondary mutation at exon 20 in EGFR, occurring in 50–60% of treated patients [9,10].